

Index

- 3-5% acetic acid, genital warts 124
- a**
- acidification, bacterial
vaginosis 267–268
- acquired immunity
bacterial vaginosis 262
M. contagiosum 103
tinea cruris 333
- acute infections, *Candida* spp.
305–306, 312–316
- acyclovir 90–91
- adhesion proteins
chancroid 280–282
mycoplasmas 236
T. vaginalis 345
- administration, vaginal probiotics 50
- AIDS *see* human immunodeficiency virus
- AIRE mutation 302–304
- amphotericin B 315
- AMPs *see* antimicrobial peptides
- AMR *see* antimicrobial resistance
- anorectal tract
Chlamydia infection 144
gonorrhea infection 188–189
- antibiotics
bacterial vaginosis 267
Chlamydia 150–151
donovanosis 176–177
gonorrhea 187, 198–200
mycoplasmas 247–248
T. pallidum 217–218
see also antimicrobial resistance
- antibodies
bacterial vaginosis 262
Chlamydia infection 146
genital tract 4–11
gonorrhea 186
herpes diagnosis 88–89
human papilloma virus 125
M. contagiosum 103
scabies 366
tinea cruris 333
T. pallidum tests 216
see also immunoglobulins
- antifungals 312–319, 336–337,
350–351
- antigenic variation, mycoplasmas 236
- antimicrobial peptides (AMPs) 282
- antimicrobial resistance (AMR)
gonorrhea 187, 199–200
mycoplasmas 247–248
T. pallidum 217–219
- antiphagocytotic proteins 282, 283–284
- antiretroviral therapies (ARTs),
HIV 73–74
- antiseptics, bacterial vaginosis 267
- antisperm antibodies 10
- antiviral therapies
genital herpes 90–94
M. contagiosum 112–113
- applications of probiotics 49–53
- arthritis, mycoplasma infections 242

- ARTs *see* antiretroviral therapies
- asymptomatic infections, *Candida* spp. 294
- attachment, *Chlamydia* 136
- autoimmunity, *Chlamydia* infection 148–150
- autolysis, gonorrhoea 185
- azithromycin 150, 176, 177, 199, 217–218, 247–248
- azoles
- Candida* spp. 312–314
 - tinea infections 336–337
 - T. vaginalis* 350–351
- b**
- bacterial vaginosis (BV) 257–274
- clinical features 263
 - diagnosis 263–266
 - epidemiology 260–261
 - G. vaginalis* 258–260
 - HIV transmission 67
 - hypotheses 257
 - immune responses 261–262
 - mycoplasma infections 238–239
 - pathogenesis 261–262
 - risk factors 260–261
 - treatment 267–268
- bacteriolysis, resistance, gonorrhoea 8–9
- balanopostitis 188
- Barnard, Christiaan 43
- bastospores 294
- B cells, mucosal immunity 11–12
- bejel (*Treponema pallidum* ssp. *endemicum*/TEN) 211–232
- Bosnia A strain 212–213
 - diagnosis 215–216
 - epidemiology 211–212, 218–222
 - genome 212–214, 217–218
 - macrolide resistance 217–219
 - treatment 217–218
 - vaccine development 222–223
 - virulence factors 214
- benzyl benzoate 367
- Bifidobacterium* 42
- biofilms, bacterial vaginosis 258–260
- biopsy, donovanosis 175
- biphasic life-cycles, *Chlamydia* 9
- blood product transfusions, HIV transmission 68
- body mass index, *Candida* infection 301
- boric acid 267–268, 315
- Bosnia A strain 212–213
- breastfeeding, *Candida* treatment 316
- buboes, chancroid 279
- BV *see* bacterial vaginosis
- c**
- calculi, urinary 242
- Candida* antigen 112
- Candida* spp. 293–327
- asymptomatic epidemiology 294
 - clinical features 305–306
 - diagnosis 306–311
 - differential diagnosis 311, 336
 - epidemiology 294–300
 - hormonal effects 300, 317–318
 - host factors 301–305, 319
 - immunocompromised patients 315–316
 - morphology 294
 - non *albicans* 299, 314–315
 - pathogenesis 300–305
 - predisposition 301–305
 - pregnancy 300–301, 316
 - probiotics 318
 - risk factors 298
 - symptomatic epidemiology 295–298
 - treatment 311–319
 - acute infection 312–316
 - general principles 311–312
 - recurrent 316–319
 - virulence factors 300–305
- cantharidine 110
- CARD9 302
- cauliflower-like papules 122–123
- CC *see* conventional circumcision
- CD4 cells
- Chlamydia* infection 147
 - HIV pathogenesis 71–72
- CD8 cells, *Chlamydia* infection 147
- cefexime 199
- ceftriaxone 199

- cell culture
 - chancroid 284
 - genital herpes 87
 - gonorrhea diagnosis 191–193
 - mycoplasmas 243–245
- cell types, mucosal immunity 10–12
- cervical ectopy, *Chlamydia*
 - infection 146
- cervicitis, mycoplasma infections 239
- chancroid (*Haemophilus ducreyi*)
 - 277–291
 - chronic limb ulcers 285–286
 - circumcision and transmission 34
 - clinical features 278–279
 - diagnosis 284
 - epidemiology 277–278
 - genomics 279–280
 - HIV transmission 65
 - immune responses 283–284
 - pathogenesis 280–284
 - prevention 285
 - treatment 284–285
- chemical treatments
 - bacterial vaginosis 267–268
 - genital warts 127
 - M. contagiosum* 110–111
- chemokine receptors, HIV
 - pathogenesis 71–72
- chemokines, *Chlamydia*
 - infection 146–150
- children
 - donovanosis 177
 - genital wart treatment 129–130
 - see also* neonates
- Chlamydia trachomatis* (*C. trachomatis*/Ct) 135–166
 - anorectal tract 144
 - autoimmunity 148–150
 - circumcision and transmission 32
 - clinical features 138–145
 - control 151–152
 - diagnosis 150–151
 - endometriosis 140
 - epidemiology 135–136
 - epididymitis 143, 149
 - female urogenital infections
 - 139–141, 146–147
 - gastrointestinal tract 144–145
 - genital tract immunity 9
 - HD-5 4
 - HIV transmission 65, 70
 - infertility 140–141, 143, 146–147, 149–150
 - lymphogranuloma
 - venereum 144–145
 - male urogenital infections 142–143, 148–150
 - orchitis 143, 149–150
 - pathogenesis 136–138, 145–150
 - persistence 137–138, 144
 - post-infection immune responses 15–16
 - pregnancy 141
 - prevention 151–152
 - prostatitis 142, 148
 - replication 137–138
 - salpingitis 140, 146–147
 - treatment 150–151
 - urogenital tract 139–143
- chloramphenicol 176
- cholera toxin B (CTB) 13
- chorioamnionitis, mycoplasma
 - infections 240
- chronic limb ulcers, *H. ducreyi* 285–286
- cidofovir 92, 112
- cimetidine 112
- ciprofloxacin 177
- circumcision
 - complications 28–29
 - methods 28
 - and prevention 27–40
 - biological reasons 27–28
 - chancroid transmission 34
 - Chlamydia* transmission 32
 - gonorrhea transmission 31–32
 - HIV transmission 29–30
 - HPV transmission 30–31, 122
 - HSV transmission 33
 - syphilis transmission 33–34
 - Trichomonas* transmission 32
 - as a public health measure 34
 - see also* female genital mutilation

- clades
 - H. ducreyi* 279–280
 - HIV 70–71
 - clarithromycin 217
 - clearance, human papilloma virus 120–121
 - clindamycin 267
 - clinical features
 - bacterial vaginosis 263
 - Chlamydia* 138–145
 - donovanosis 170–174
 - genital herpes 86–87
 - genital warts 122–124
 - gonorrhea 188–189
 - M. contagiosum* 106–107
 - mycoplasmas 238–243
 - scabies 359–363
 - tinea cruris 333–335
 - T. vaginalis* 346–348
 - vulvovaginal candidosis 305–306
 - clitoridectomy 35
 - combination antiretroviral therapies, HIV 74
 - complement-mediated bacteriolysis, gonorrhea 8–9
 - complications
 - azole antifungals 312
 - circumcision 28–29
 - donovanosis 174–175
 - female genital mutilation 35–36
 - condylomata lata 125–126
 - contaminated blood, HIV transmission 68
 - contraceptives
 - Candida* infection 317–318
 - HIV replication levels 69
 - control
 - Chlamydia* infections 151–152
 - donovanosis 177–178
 - genital herpes 93–94
 - gonorrhea 200–201
 - mycoplasma infections 248–249
 - scabies 368
 - T. vaginalis* 351
 - conventional circumcision (CC) 28
 - co-trimoxazole 176
 - counseling, genital herpes patients 94
 - CpxRA 283
 - crotamiton 367
 - crusted scabies 362, 368
 - cryotherapy
 - genital warts 126–127
 - M. contagiosum* 109
 - CS 21 barrier gel 93
 - Ct* see *Chlamydia trachomatis*
 - CTB see cholera toxin B
 - C. trachomatis* see *Chlamydia trachomatis*
 - culture
 - Candida* 310
 - chancroid 284
 - gonorrhea 191–193
 - herpes 87
 - mycoplasmas 243–245
 - tinea cruris 337
 - T. vaginalis* 349
 - cytokines
 - bacterial vaginosis 261–262
 - Chlamydia* infection 146–150
 - HIV transmission 69–70
 - mycoplasma-mediated induction 237
 - cytology, mucosal immunity 10–12
- d**
- DC cells, mucosal immunity 12
 - dectin-1 304
 - Dedicator of cytokinesis 8 (DOCK8) deficiency 103
 - defenses, HIV transmission to females 66
 - defensins, humoral immunity 4
 - dermatoscopy
 - scabies 363–365
 - M. contagiosum* 105
 - diagnosis
 - bacterial vaginosis 263–266
 - chancroid 284
 - Chlamydia* 150–151
 - donovanosis 175–176
 - genital herpes 87–89
 - genital warts 124–126
 - gonorrhea 189–198
 - HIV infections 72–73

- M. contagiosum* 103–106
 mycoplasmas 243–247
 scabies 363–366
 tinea cruris 336–337
T. pallidum 215–216
T. vaginalis 348–350
 vulvovaginal candidosis 306–311
- differential diagnosis
 Candida infections 311, 336
 chancroid 284
 donovanosis 176
 genital warts 125–126
 tinea cruris 336
- disposable suture devices (DSD) 28
- disseminated infections
 gonorrhea 188–189
 H. ducreyi 285–286
 mycoplasmas 242
- DltA 282
- DOCK8 *see* Dedicator of cytokinesis 8
- Döderlein's bacilli 41
- donovanosis 167–179
 classifications 171
 clinical features 170–174
 complications 174–175
 control 177–178
 diagnosis 175–176
 differential diagnosis 176
 epidemiology 168
 history 167
 and HIV 173–174
 incubation period 169
 pathology 168–169
 prevention 177–178
 sequelae 174–175
 sites of involvement 174
 treatment 176–177
- doxycycline 150, 177, 217
- drug sensitivity, probiotics 45–46
- DSD *see* disposable suture devices
- DsrA 281–282
- e**
- early adverse events,
 circumcision 28–29
- echinocandins 314–315
- efflux pump inhibitors 200
- Ehrlich, Paul 41–42
- electrocautery, genital warts 127
- elementary bodies, *Chlamydia* 9,
 137–138
- elephantiasis 171, 173
- ELISA *see* enzyme-linked
 immunosorbent assay
- endometriosis
 Chlamydia infection 140
 mycoplasma infections 239
- entry, *Chlamydia* 136–137
- entry inhibitors, HIV 73–74
- env* genes 62–63
- environmental factors, tinea cruris 332
- enzyme-linked immunosorbent assay
 (ELISA) tests
 Chlamydia 150
 scabies 366
- enzymes, mycoplasmas 236–237
- epidemiology
 bacterial vaginosis 260–261
 Candida spp. 294–300
 chancroid 277–278
 Chlamydia 135–136, 143
 donovanosis 168
 gonorrhea 182, 186–187
 herpes 84
 human papilloma virus 121
 M. contagiosum 101–102
 mycoplasmas 237–238
 scabies 357–358
 tinea cruris 330–331
 Treponema species 211–212, 218–222
 T. vaginalis 342–344
- epididymitis
 Chlamydia infection 143, 149
 mycoplasma infections 241
- epithelial cells, mucosal immunity 10
- erythrasma 336
- erythromycin 177, 217
- ESCs *see* extended-spectrum
 cephalosporins
- estrogen, *Candida* infection 318
- excision
 donovanosis 177
 genital warts 127
 M. contagiosum 109

extended-spectrum cephalosporins
(ESCs), gonorrhea 187

extraction-curettage
genital warts 127
M. contagiosum 109

extragenital locations
gonorrhea 188–189
mycoplasmas 242

f

facultative intracellular localization,
mycoplasmas 237

fallopian tube inflammation *see* salpingitis

famciclovir 91–92

FcRn *see* neonatal Fc receptor

female genital mutilation
(FGM) 35–36

female reproductive tract (FRT)
Chlamydia infection 139–141,
146–147
definition 139
gonorrhea infections 188
HIV transmission 66–68
humoral immunity 2–4
immunoglobulins 4–7, 11
mycoplasma infections 238–240

female-to-male transmission, HIV,
circumcision 29–30

fetal infection
herpes 85
HIV 68
mycoplasmas 238

FGM *see* female genital mutilation

fibrinogen adhesion,
chancroid 280–282

FISH *see* fluorescence *in situ*
hybridization

Flp proteins 281, 283

fluconazole 312–314, 316

flucytosin 315

fluorescence *in situ* hybridization (FISH),
bacterial vaginosis 264–265

Fluorescent Treponemal Antibody
Absorption test (FTA-Abs) 216

fluoroquinolones
gonorrhea treatment 200
mycoplasma treatment 247–248

foreskins
STI acquisition 27–28
see also circumcision

foscarnet 91–92

FRT *see* female reproductive tract

FTA-Abs *see* Fluorescent Treponemal
Antibody Absorption test

Fuller, Roy 44

g

gag genes 62–63

Gardnerella vaginalis (*G.*
vaginalis) 258–260

gastrointestinal tract
Chlamydia infection 144–145
lymphogranuloma
venereum 144–145
probiotics 41–43

genital herpes 83–99
clinical features 86–87
control 94
diagnosis 87–89
epidemiology 84
immunity 85–86
pathogenesis 84–86
prevention 93–94
reactivation 85
structure 83–84
transmission 85
treatment 90–93

genital mycoplasmas 233–255
adhesion proteins 236
antigenic variation 236
arthritis 242
biology 234–235
clinical features 238–243
control 248–249
cytokine induction 237
diagnosis 243–247
enzymes 236–237
epidemiology 237–238
genomes 234–235, 236
HIV positive patients 242–243
immunocompromised
patients 242–243
infertility 240–242
intracellular localization 237

- morphology 235–236
- pathogenesis 235–237
- pathogenicities 233–234
- prevention 248–249
- treatment 247–248
- genital tracts
 - Chlamydia* infection 139–143, 146–149
 - complement 8–9
 - HIV transmission 66–68
 - immunoglobulin-producing cells 10–12
 - immunoglobulins 4–12
 - cellular basis 10–12
 - functions 8–10
 - origins 7–8
 - post-infection 15–17
 - induction of immune response 12–17
 - innate immunity 2–4
 - mucosal immunity 1–26
 - see also* female reproductive tract; male reproductive tract
- genital ulcer disease (GUD)
 - circumcision and transmission 32–34
 - see also* chancroid; Herpes simplex virus; syphilis
- genital warts 119–133
 - clearance 120–121
 - clinical features 122–124
 - diagnosis 124–126
 - differential diagnosis 125–126
 - epidemiology 121
 - immunocompromised patients 129
 - pregnancy 129
 - protective factors 122
 - risk factors 121–122
 - transmission 120
 - treatment 126–130
 - see also* human papilloma virus
- genomes
 - gonorrhea 185
 - H. ducreyi* 279–280
 - HIV 62–63
 - M. contagiosum* 102
 - mycoplasmas 234–235, 236
 - T. pallidum* spp. 212–214, 217–218
 - genotyping, gonorrhea 193–197
 - gentamycin 176
 - giant *Molluscum contagiosum* 106–107
 - glands of Littre, immunoglobulins 11
 - glucose tolerance, *Candida* infection 301, 319
 - gonorrhea (GN) 181–209
 - antibiotic resistance 187
 - antimicrobial resistance 199–200
 - circumcision and transmission 31–32
 - clinical features 188–189
 - complement resistance 8–9
 - control 200–201
 - diagnosis 189–198
 - epidemiology 182, 186–187
 - extragenital locations 188–189
 - genital tract immunity 8–9
 - genome 185
 - genotyping 193–197
 - HD-5 4
 - HIV transmission 65, 70
 - identification 192–193
 - IgA1 proteases 6
 - immunity 186
 - nucleic acid amplification tests 194–198
 - pathogenesis 185–186
 - physiology 185
 - post-infection immune responses 15
 - prevention 200–201
 - treatment 198–200
 - vaccination 201
 - virulence factors 183–185
 - gp120 protein 71–72
 - gram-negative bacteria
 - Chlamydia* 135–166
 - donovanosis 167–179
 - gonorrhea 181–209
 - G. vaginalis* 258–260
 - H. ducreyi* 277–291
 - mycoplasmas 233–255
 - oxidase-positive characteristics 192
 - T. pallidum* and sub-species 211–232
 - vaginal microflora 47

- gram-positive bacteria, vaginal microflora 47
- granuloma donovani/inguinale/venereum *see* donovanosis
- griseofulvin 336
- GUD *see* genital ulcer disease
- h**
- HAART *see* highly active antiretroviral treatment
- Haemophilus ducreyi* (*H. ducreyi*/chancroid) 277–291
- chronic limb ulcers 285–286
- circumcision and transmission 34
- clinical features 278–279
- diagnosis 284
- epidemiology 277–278
- genomics 279–280
- HIV susceptibility 65
- immune responses 283–284
- pathogenesis 280–284
- prevention 285
- treatment 284–285
- virulence factors 280–283
- HD-5, male genital tract 4
- H. ducreyi see Haemophilus ducreyi*
- healthcare workers, HIV as occupational risk 68
- healthy non-Lactobacillus dominated vaginal flora 47–49
- heat-shock protein 60 (Hsp60) 145
- helicase blockers 93
- herpes simplex viruses (HSV) 83–99
- circumcision and transmission 33
- clinical features 86–87
- control 94
- diagnosis 87–89
- epidemiology 84
- HIV relationship 33
- HIV transmission 65
- immunity 85–86
- pathogenesis 84–86
- prevention 93–94
- reactivation 85
- structure 83–84
- transmission 85
- treatment 90–93
- HgbA 282
- highly active antiretroviral treatment (HAART) 74
- histology, *Candida* infections 311
- histopathology
- genital warts 124–125
- scabies 365–366
- HIV *see* human immunodeficiency virus
- horizontal gene transfer, *T. pallidum* spp. 213
- hormonal variations
- Candida* infection 300, 317–318
- HIV transmission 67–68
- host factors
- M. contagiosum* 103
- sexual HIV transmission 69–70
- tinea cruris 332–333
- vulvovaginal candidosis 301–305, 319
- HPV *see* human papilloma virus
- Hsp60 *see* heat-shock protein 60
- HSV *see* herpes simplex viruses
- human immunodeficiency virus (HIV) 61–81
- circumcision 29–30
- clades 70–71
- contaminated blood/blood products 68
- diagnosis 72–73
- donovanosis 173–174
- female genital mutilation 35–36
- genome 62–63
- HSV2 relationship 33
- infectivity
- host factors 69–70
- viral factors 70–71
- initial symptoms 61–62
- M. contagiosum* 107, 112
- mycoplasma infections 242–243
- occupational risks 68–69
- pathogenesis 71–72
- post-infection immune responses 16
- quasispecies 74
- structure 62–63
- therapeutics 73–74
- transmission

- bacterial vaginosis 67
- circumcision 29–30
- contaminated blood/blood products 68
- female genital mutilation 35–36
- female genital tract 66–68
- hormonal variations 67–68
- host factors 69–70
- inflammation 67
- inner prepuce 27–28
- maternal–fetal 68
- non-ulcerative infections 65
- occupation risks 68–69
- routes 64–69
- shared syringes & needles 68
- T. vaginalis* 344–345
- ulcerative infections 64–65
- viral factors 70–71
- human papilloma virus (HPV) 119–133
 - circumcision and transmission 30–31
 - clearance 120–121
 - clinical features 122–124
 - diagnosis 124–126
 - differential diagnosis 125–126
 - epidemiology 121
 - immune interactions 120
 - immunocompromised patients 129
 - life cycle 120
 - mucosal immunity 10
 - post-infection immune responses 16–17
 - risk factors 121–122
 - taxonomy 119–120
 - transmission 120, 121–122
 - treatment 126–130
 - vaccination 130–131
- humoral immunity
 - bacterial vaginosis 261–262
 - Chlamydia* infection 146
 - female genital tract 2–4
 - human papilloma virus 120
 - induction 14
 - male genital tract 4
 - M. contagiosum* 103
 - tinea cruris 333
- hyperpigmented pityriasis versicolor 336
- hypertrophic borders, donovanosis 171
- hypha 294
- i**
- IDO *see* indoleamine 2,3 dioxygenase
- IgA1 proteases 6, 185, 237
- IgA
 - female genital tract 6–7
 - mucosal immunity 7–8, 10–11
- IgG
 - female genital tract 6
 - herpes diagnosis 88–89
 - mucosal immunity 7–8, 10–11
- IgM
 - herpes diagnosis 88–89
 - mucosal immunity 8
- imiquimod 111–112, 127
- immune modulators
 - genital warts 127–129
 - M. contagiosum* 111–112
- immunity
 - bacterial vaginosis 261–262
 - chancroid 283–284
 - Chlamydia* infection 146–150
 - gonorrhea 186
 - herpes viruses 85–86
 - human papilloma virus 120
 - immunoglobulins 4–11
 - innate 2–4
 - M. contagiosum* 103
 - mucosal 1–26
 - mycoplasma-mediated induction 237
 - tinea cruris 333
- immunization, genital tract responses 13–14
- immunocompromised patients
 - Candida* infections 315–316
 - genital warts 129
 - M. contagiosum* 107, 112–113
 - mycoplasma infections 242–243
- immunoflorescent tests, genital herpes 87–88

- immunoglobulins
 - bacterial vaginosis 262
 - Chlamydia* infection 146
 - genital tract 4–17
 - cellular basis 10–12
 - female 4–7
 - functions 8–10
 - post-infection 15–17
 - gonorrhea 186
 - herpes diagnosis 88–89
 - human papilloma virus 125
 - M. contagiosum* 103
 - scabies 366
 - tinea cruris 333
 - T. pallidum* tests 216
 - see also* antibodies
 - IN *see* integrases
 - inclusions, *Chlamydia* 137–138
 - incubation, donovanosis 169
 - indoleamine 2,3 dioxygenase (IDO) 284
 - induction
 - Chlamydia* replication 138
 - genital tract immune responses 12–17
 - herpes 85
 - infectivity
 - HIV
 - host factors 69–70
 - viral factors 70–71
 - infertility
 - antibodies 10
 - Chlamydia* infection 140–141, 143, 146–147, 149–150
 - mycoplasma infections 240, 241–242
 - infibulation 35
 - inflammation
 - Chlamydia* infection 139–143, 146–150
 - HIV transmission 67, 69–70
 - inherent vulnerabilities, HIV
 - transmission to females 66–67
 - initial symptoms
 - genital herpes 86
 - HIV 61–62
 - innate immunity 2–4
 - bacterial vaginosis 261–262
 - tinea cruris 333
 - inner prepuce, STI acquisition 27–28
 - integrase inhibitors 73–74
 - integrases (IN), HIV 63
 - interferon alpha, *M. contagiosum* 112
 - interleukins
 - bacterial vaginosis 262
 - vulvovaginal candidosis 304
 - intracellular localization,
 - mycoplasmas 237
 - intralesional immunotherapy, *M. contagiosum* 112
 - itraconazole 336–337
 - ivermectin 367
- k**
- keratotic warts 122–123
 - Klebsiella granulomatis* 167–179
 - see also* donovanosis
 - KOH *see* potassium hydroxide
- l**
- lactic acid, lactobacilli 41
 - Lactobacillus*
 - acidophilus* 54
 - Candida* treatment 318
 - casei* 42–43
 - lactic acid 41
 - reuteri* 52
 - rhamnosus* GG 43
 - rhamnosus* GR-1 52
 - urinary tract infections 52
 - vaginal microflora 47–48
 - vaginosis 51
 - lactoferrin, humoral immunity 3, 4
 - Langerhans cells
 - HPV clearance 121
 - inner prepuce 27
 - laser therapy, genital warts 127
 - late complications,
 - circumcision 28–29
 - Lavoisier, Antoine L. de 41
 - lentiviruses* 62
 - see also* human immunodeficiency virus
 - LGV *see* lymphogranuloma venereum
 - life cycles, human papilloma virus 120

- lifestyle
Candida infection 319
 tinea cruris 332
- Lily, Daniel M. 43–44
- limb ulcers, *H. ducreyi* 285–286
- lindane 367
- lipooligosaccharide (LOS) 184, 284
- lipopolysaccharide (LPS), *Chlamydia* infection 149
- local host factors, HIV infectivity 69–70
- LOS *see* lipooligosaccharide
- lymphogranuloma venereum (LGV), *Chlamydia* 144–145
- lysozyme, humoral immunity 3, 4
- m**
- macrolides
 mycoplasma treatment 247–248
T. pallidum treatment 217–219
- macrophages
 chancroid 280–282
Chlamydia infection 146–147
 mucosal immunity 12
- malathion 367
- male circumcision (MC) 27–40
 complications 28–29
 methods 28
 and prevention 27–40
 biological reasons 27–28
 chancroid transmission 34
Chlamydia transmission 32
 gonorrhea transmission 31–32
 HIV transmission 29–30
 HPV transmission 30–31
 HSV transmission 33
 syphilis transmission 33–34
Trichomonas transmission 32
 as a public health measure 34
- male reproductive tract (MRT)
Chlamydia 142–143, 148–150
 definition 142
 gonorrhea infections 188
 humoral immunity 4, 14
 immunoglobulins 11
 mycoplasma infections 241–242
- male-to-female transmission, HIV, circumcision 29
- management, genital herpes 93–94
- mannose binding lectin (MBL), *Candida* infection 301–302, 304–305
- maternal–fetal transmission
Chlamydia 141
 herpes 85
 HIV 68
 HPV 120
 mycoplasmas 238
- MB *see* multibanded antigen
- MBL *see* mannose binding lectin
- MC *see* male circumcision
- MCV *see* *Molluscum contagiosum* virus
- meatal stenosis, circumcision 28–29
- Mechnikov, Ilya I. 41
- men who have sex with men (MSM)
 anorectal *Chlamydia* infection 143
 circumcision
 and HIV transmission 30
 and ulcerative infection
 transmission 33
 HIV transmission, and
 circumcision 30
- MeNZB vaccine 201
- methods of circumcision 28
- metronidazole 267, 350–351
- MGEs *see* mobile genetic elements
- MgPa operon 236
- MIC *see* minimum inhibitory concentrations (MIC)
- microflora, vaginal 46–49
- microscopy
 gonorrhea diagnosis 191
 scabies 363
T. vaginalis 348–349
 vulvovaginal candidosis 307–310
- minimum inhibitory concentrations (MIC), probiotics 45–46
- Mjölksyra 41
- MLST *see* multilocus sequence typing
- mobile genetic elements (MGEs), gonorrhea 185
- modithromycin 200
- molecular typing, *T. pallidum* 220–222

- Molluscum contagiosum* virus
 (MCV) 101–118
 antiviral drug treatments 112–113
 chemical treatments 110–111
 clinical features 106–107
 diagnosis 103–106
 epidemiology 101–102
 HIV positive patients 107, 112
 immune modulator
 treatments 111–112
 immunity 103
 pathogenesis 102–103
 procedure-based
 treatments 109–110
 transmission 107
 treatment 107–113
- morphology
Candida 294
Chlamydia 146
 gonorrhoea 182
 herpes simplex viruses 83–84
 human immunodeficiency
 virus 62–63
 mycoplasmas 235–236
see also structure
- motility, mycoplasmas 235
 moxifloxacin 247–248
 MRP8 *see* myeloid-related protein-8
 MRT *see* male reproductive tract
 MSM *see* men who have sex with men
 MTR *see* multiple transferable
 resistance transporter
- mucins 4
- mucosal immunity 1–26
 cellular basis 10–12
 epithelial cells 10
 HIV transmission 66
 immunoglobulins 4–11
 innate 2–4
 post-infection 15–17
- multibanded antigen (MB) 236
- multilocus sequence typing
 (MLST) 193–197
- multiple transferable resistance (MTR)
 transporter 282
- mutations, *T. pallidum* AMR
 strains 217–219
- mycological culture 310
- Mycoplasma* spp. 233–255
 adhesion proteins 236
 antigenic variation 236
 arthritis 242
 clinical features 238–243
 control 248–249
 cytokine induction 237
 diagnosis 243–247
 enzymes 236–237
 epidemiology 237–238
 genomes 234–235, 236
 HIV positive patients 242–243
 immunocompromised
 patients 242–243
 infertility 240–242
 intracellular localization 237
 morphology 235–236
 pathogenesis 235–237
 pathogenicities 233–234
 prevention 248–249
 treatment 247–248
- myeloid-related protein-8 (MRP8) 70
- n**
- NAATs *see* nucleic acid amplification tests
- NALP3/CIAS1 304
- needles, HIV transmission 68
- Neisseria gonorrhoeae* (*N.*
gonorrhoeae) 181–209
 antibiotic resistance 187
 clinical features 188–189
 complement resistance 8–9
 control 200–201
 diagnosis 189–198
 epidemiology 182, 186–187
 extragenital locations 188–189
 genital tract immunity 8–9
 genotyping 193–197
 HD-5 4
 identification 192–193
 IgA1 proteases 6
 immunity 186
 morphology 182
 nucleic acid amplification
 tests 194–198
 pathogenesis 185–186

- post-infection immune responses 15
 - prevention 200–201
 - treatment 198–200
 - vaccination 201
 - virulence factors 183–185
 - neonatal Fc receptor (FcRn) 7–8
 - Chlamydia* 137
 - neonates
 - Chlamydia* transmission 141
 - donovanosis 177
 - gonorrhea infections 189
 - herpes transmission 85
 - HIV transmission 68
 - HPV transmission 120
 - mycoplasma transmission 238
 - vaginal microflora 47
 - see also children
 - neutrophils, *Chlamydia*
 - infection 146–147
 - N. gonorrhoeae* see *Neisseria gonorrhoeae*
 - NGU see nongonococcal urethritis
 - Nichols-like *Treponema pallidum*
 - strain 213–214, 220–222
 - nitroimidazole 267–268
 - NK cells, mucosal immunity 12
 - N. meningitidis*, complement-mediated bacteriolysis 9
 - NNRTIs see nonnucleoside reverse transcriptase inhibitors
 - nodular scabies 362
 - nongonococcal urethritis (NGU) 142, 148, 241
 - nonnucleoside reverse transcriptase inhibitors (NNRTIs), HIV 73
 - non-ulcerative infections
 - circumcision and transmission 31–32
 - HIV transmission 65
 - see also *Chlamydia trachomatis*; gonorrhea; *Trichomonas vaginalis*
 - NRTIs see nucleoside reverse transcriptase inhibitors
 - nucleic acid amplification tests (NAATs)
 - bacterial vaginosis 264–266
 - Candida* infections 310–311
 - Chlamydia* 150
 - gonorrhea 194–198
 - mycoplasmas 245–246
 - positive predictive value 198
 - scabies 366
 - tinea cruris 337
 - T. pallidum* 215–216, 217–218
 - T. vaginalis* 350
 - see also polymerase chain reaction
 - nucleoside reverse transcriptase inhibitors (NRTIs), HIV 73
 - nystatine 315
- O**
- obstetrics and gynecology (OB/GYN),
 - probiotics 50–53
 - occupation risk, HIV
 - transmission 68–69
 - octenidine dihydrochloride 267
 - Opa see opacity proteins
 - opacity proteins (Opa) 184
 - OppA 236
 - orchitis
 - Chlamydia* infection 143, 149–150
 - mycoplasma infections 241
 - origins, genital tract antibodies 7–8
 - Osom Trich distick 349
 - ovarian function, *Chlamydia* 140–141
 - oxidase-positive gram-negative bacteria 192
- P**
- parasitophorous vacuoles, *Chlamydia* 137
 - Pasteur, Louis 41
 - pathogenesis
 - bacterial vaginosis 261–262
 - Candida* spp. 300–305
 - chancroid 280–284
 - Chlamydia* 136–138, 145–150
 - donovanosis 168–169
 - gonorrhea 185–186
 - herpes 84–86
 - HIV 71–72
 - M. contagiosum* 102–103
 - mycoplasmas 235–237
 - scabies 358–359
 - tinea cruris 332–334
 - T. vaginalis* 345–346

- PCR *see* polymerase chain reaction
- PDL *see* pulsed dye laser
- pelvic inflammatory disease (PID) 139–140
- gonorrhea 188
- mycoplasma infections 239–240
- T. vaginalis* 348
- penciclovir 92
- penicillin 217
- peptide nucleic acid (PNA) probes 264–265
- perinatal herpes infections 85
- permethrin 366–367
- peroxidases, humoral immunity 3, 4
- persistence, *Chlamydia* 137–138, 144
- pH, *Candida* infections 310
- phagocytosis resistance, chancroid 283–284
- pharmacological treatments
- bacterial vaginosis 267
 - chancroid 284–285
 - Chlamydia* 150–151
 - donovanosis 176–177
 - genital herpes 90–94
 - genital warts 127–129
 - gonorrhea 198–200
 - HIV 73–74
 - M. contagiosum* 110–113
- pharyngeal infections, gonorrhea 189
- phase switching, mycoplasmas 236
- physiology, gonorrhea 185
- pIgR *see* polymeric immunoglobulin receptors
- pinta (*Treponema carateum*) *see* *Treponema pallidum* ssp. *pallidum*
- PIs *see* protease inhibitors
- pityriasis versicolor 336
- placental transport
- HIV transmission 68
 - immunoglobulins 7–8
- plaques, genital warts 122, 124
- PNA *see* peptide nucleic acid
- podophyllotoxin 111, 127
- pol* genes 62–63
- polymerase chain reaction (PCR) tests
- bacterial vaginosis 264–266
 - Candida* infections 310–311
 - chancroid 284
 - Chlamydia* 150
 - donovanosis 176
 - genital herpes 87–88
 - gonorrhea 194–198
 - M. contagiosum* 105
 - mycoplasmas 245–246
 - scabies 366
 - tinea cruris 337
 - T. pallidum* 215–216, 217–218
- polymeric immunoglobulin receptors (pIgR) 7–8
- polymorphonuclear cells (PMNs), chancroid 280
- Por *see* porins
- porins (Por) proteins 183–184
- positive predictive value (PPV) 198
- post-infection immune responses 15–17
- postmenopause
- vaginal microflora 48
 - vulvovaginal candidosis 298–300
- potassium hydroxide (KOH)
- M. contagiosum* 110–111
 - tinea cruris 336–337
- poxviruses 102
- see also* *Molluscum contagiosum* virus
- PPV *see* positive predictive value
- predisposition to *Candida* infection 301–302
- pregnancy
- Candida* infection 300–301, 316
 - Chlamydia* 141
 - genital warts 129
 - mycoplasma infections 240
 - probiotics 52–53
 - T. vaginalis* 348, 351
- pre-menarche
- vaginal microflora 47–48
 - vulvovaginal candidosis 298–300
- preterm births, mycoplasma infections 240
- prevention
- chancroid 285
 - Chlamydia* infections 151–152
 - by circumcision 27–40
 - biological reasons 27–28

- chancroid transmission 34
- Chlamydia* transmission 32
- gonorrhea transmission 31–32
- HIV transmission 29–30
- HPV transmission 30–31, 122
- HSV transmission 33
- syphilis transmission 33–34
- Trichomonas* transmission 32
- donovanosis 177–178
- genital herpes 93–94
- gonorrhea 200–201
- HPV transmission 122, 130–131
- mycoplasma infections 248–249
- scabies 368
- tinea cruris 338
- T. vaginalis* 351
- primary scabies 359–360
- probiotics
 - administration 50
 - applications 49–53
 - bacterial vaginosis 268
 - Candida* infections 318
 - definitions 43–46
 - drinks 43
 - drug sensitivity 45–46
 - evolving descriptions of 45
 - gastrointestinal tract 41–43
 - history of 41–43, 45
 - minimum inhibitory concentrations (MIC) 45–46
 - normal vaginal microflora 46–49
 - pregnancy 52–53
 - reproductive health 41–59
 - urinary tract infections 52
 - vaginitis 50–51
- procedure-based treatments, *M. contagiosum* 109–110
- proctitis, *Chlamydia* infection 144
- progesterone, HIV
 - transmission 67–68
- prostatitis
 - Chlamydia* 142, 148
 - mycoplasma infections 241
- protease inhibitors (PIs), HIV 73
- proteases (PR), HIV 63
- protective factors, HPV acquisition 122
- pseudo-bubos 170
- pseudomembranous tinea 335
- pseudomycelium 294
- public health, and circumcision 34
- pulsed dye laser (PDL), *M. contagiosum* 109–110
- q**
 - quantitative polymerase chain reaction (qPCR) tests 264–266
 - quasispecies, HIV 74
 - quinolones 247–248
- r**
 - rabbit infectivity test (RIT) 215
 - Rapid Plasma Reagin (RPR) tests, *T. pallidum* 216
 - reactivation, herpes 85
 - recurrent tinea infections 338
 - recurrent vulvovaginal candidosis (RVVC) 295–298, 306, 316–319
 - reduction modifiable (Rmp)
 - proteins 184
 - regulation, *H. ducreyi*
 - virulence 282–283
 - reinfection
 - Chlamydia* 144
 - T. vaginalis* 351
 - replication, *Chlamydia* 137–138
 - reproduction, gonorrhea 185
 - reproductive age, vaginal microflora 47–48
 - reproductive health, probiotics 41–59
 - resistance
 - antifungal 317, 350
 - antimicrobial
 - gonorrhea 187, 199–200
 - mycoplasmas 247–248
 - T. pallidum* 217–218
 - reticulate bodies
 - Chlamydia* 137–138
 - C. trachomatis* 9
 - reverse transcriptases (RT), HIV 63
 - risk factors
 - bacterial vaginosis 260–261
 - HPV acquisition 121–122
 - T. vaginalis* 342–344
 - vulvovaginal candidosis 298

- RIT *see* rabbit infectivity test
 Rmp proteins *see* reduction modifiable proteins
 RPR *see* Rapid Plasma Reagin tests
 RT *see* reverse transcriptases
 RVVC *see* recurrent vulvovaginal candidosis
- S**
- salicylic acid, *M. contagiosum* 111
Salmonella typhi Ty21a vaccine 13–14
 salpingitis
 Chlamydia infection 140, 146–147
 gonorrhea 188
 mycoplasma infections 239–240
 Sap transporter 282
 scabies (*Sarcoptes scabiei*) 357–371
 clinical features 359–363
 control 368
 crusted 362, 368
 diagnosis 363–366
 epidemiology 357–358
 pathogenesis 358–359
 prevention 368
 treatment 366–368
 Scheele, Carl w. 41
 SDA *see* strand displacement amplification
 secondary scabies 360
 sensibility, gonorrhea diagnostic tests 190
 sequelae
 donovanosis 174–175
 mycoplasma infections 239–240
 serologic tests
 mycoplasmas 246–247
 T. pallidum 216
 see also antibodies; immunoglobulins
 serovars, *Chlamydia* 135–136
 severe vulvitis 314
 sexual transmission
 HIV 64–68, 69–71
 human papilloma virus 120, 121–122
 Shang Ring (SR), circumcision 28
 shared syringes and needles, HIV transmission 68
 Shirota, Minoru, Dr 42
 signal transducer and activator of transcription 1 (STAT1) 302
 sinecatechins 129
 single-stranded RNA (ssRNA), HIV 62–63
 smooth papules, genital warts 122
 specificity, gonorrhea diagnostic tests 190
 spiramycin 217
 SR *see* Shang Ring
 SS14-like *Treponema pallidum* strains 213–214, 220–222
 ssRNA *see* single-stranded RNA
 STAT1 *see* signal transducer and activator of transcription 1
 sterols 235
 Stillwell, Rosalie H. 43–44
 strand displacement amplification (SDA) 195
 structure
 Chlamydia 146
 gonorrhea 182
 herpes simplex viruses 83–84
 HIV 62–63
 mycoplasmas 235–236
 sulfur preparations for scabies 367
 sulphamethoxazole 176
 sulphonamide 176
 surgical interventions,
 donovanosis 177
 symptomatic infection, *Candida* spp. 295–298
 symptoms
 genital warts 123–124
 see also clinical presentation
 syphilis (*Treponema pallidum* ssp. *pallidum*/TPA) 211–232
 circumcision and
 transmission 33–34
 condylomata lata 125–126
 diagnosis 215–216
 epidemiology 211–212, 218–222
 genome 212–214, 217–218
 macrolide resistance 217–219
 molecular typing 220–222
 treatment 217–218
 vaccine development 222–223
 virulence factors 214

- syringes, HIV transmission 68
 systemic host factors, HIV infectivity 69
 systemic infections, mycoplasmas 242
- t**
- T3SS *see* Type III secretion system
 proteases
- TadA 282
- taxonomy, human papilloma
 virus 119–120
- T cells
 chancroid 280–282, 283–284
Chlamydia infection 146–147
 HIV pathogenesis 71–72
 mucosal immunity 11–12
- TEN *see Treponema pallidum* ssp.
endemicum
- tenofovir 94
- terbinafine 336
- tetracycline and derivatives 200, 217,
 247–248
- Tfp *see* type IV pili
- therapeutics, HIV 73–74
- thiamphenicol 176
- Thymbra capitata* essential oil 268
- thymidine kinase (TK) 90
- tinea cruris 329–340
 clinical features 333–335
 diagnosis 336–337
 differential diagnosis 336
 epidemiology 330–331
 host factors 332–333
 immune responses 333
 pathogenesis 332–334
 prevention 338
 recurrent 338
 transmission 331
 treatment 337–338
 variants 335
- tinea incognito 335
- tinidazole 267
- Tissier, Henry 42
- TK *see* thymidine kinase
- TLRs *see* toll-like receptors
- TMA *see* transcription-mediated
 amplification
- toll-like receptors (TLRs) 261–262, 304
- Ton-B-dependent receptors 282
- topical agents
 genital warts 127–129
M. contagiosum 110–111
 scabies 366–367
 tinea infections 337
- TPA *see Treponema pallidum* ssp.
pallidum
- TPE (*Treponema pallidum* ssp.
pertenue/yaws) *see Treponema*
pallidum ssp. *pallidum*
- Tpr proteins 214
- tranfusions, HIV transmission 68
- transcription-mediated amplification
 (TMA) 195
- transmission
 bacterial vaginosis 260–261
Candida spp. 298
Chlamydia, circumcision effects 32
 gonorrhoea, circumcision
 effects 31–32
 herpes simplex viruses 85
- HIV
 bacterial vaginosis 67
 circumcision effects 29–30
 contaminated blood/blood
 products 68
 female genital mutilation
 effects 35–36
 female genital tract 66–68
 hormonal variations 67–68
 host factors 69–70
 inflammation 67
 maternal–fetal 68
 non-ulcerative infections 65
 occupation risks 68–69
 routes 64–69
 shared syringes and needles 68
T. vaginalis 344–345
 ulcerative infections 64–65
 viral factors 70–71
- HPV 120, 121–122
 circumcision effects 30–31
- M. contagiosum* 107
- tinea cruris 331
- Trichomonas*
 circumcision effects 32
 probiotics 53
- T. vaginalis* 344

treatment

- bacterial vaginosis 267–268
- chancroid 284–285
- Chlamydia* 150–151
- donovanosis 176–177
- genital herpes 90–94
- genital warts 126–130
- gonorrhoea 198–200
- HIV 73–74
- M. contagiosum* 107–113
- mycoplasmas 247–248
- scabies 366–368
- tinea infections 337–338
- T. pallidum* 217–218
- T. vaginalis* 350–351
- vulvovaginal candidosis 311–319
- Treponema carateum* (pinta) 211
 - see also *Treponema pallidum* ssp. *pallidum*
- Treponema pallidum* ssp. *endemicum* (bejel/TEN) 211–232
 - Bosnia A strain 212–213
 - see also *Treponema pallidum* ssp. *pallidum*
- Treponema pallidum* ssp. *pallidum* (syphilis/TPA) 211–232
 - circumcision and transmission 33–34
 - condylomata lata 125–126
 - diagnosis 215–216
 - epidemiology 211–212, 218–222
 - genome 212–214, 217–218
 - macrolide resistance 217–219
 - molecular typing 220–222
 - treatment 217–218
 - vaccine development 222–223
 - virulence factors 214
- Treponema pallidum* ssp. *pertenue* (yaws/TPE) 211, 285–286
 - see also *Treponema pallidum* ssp. *pallidum*
- triazoles 312–314
- trichloroacetic acid 127
- Trichomonas vaginalis* (*T. vaginalis*/Tv) 341–356
 - circumcision and transmission 32
 - clinical features 346–348

- diagnosis 348–350
 - epidemiology 342–344
 - HIV 344–345
 - pathogenesis 345–346
 - pregnancy 348, 351
 - probiotics 53
 - reinfection 351
 - transmission 344
 - treatment 350–351
 - virulence 345–346
 - trimethoprim 176
 - tumor necrosis factor (TNF), HIV 70
 - Tv/*T. vaginalis* see *Trichomonas vaginalis*
 - Type III secretion system (T3SS)
 - proteases 137
 - type IV pili (TfP) 183
- u**
- ulcerating granuloma of the pudenda see donovanosis
 - ulcerative infections
 - circumcision and transmission 32–34
 - HIV transmission 64–65
 - see also chancroid; donovanosis; herpes simplex virus; syphilis
 - ulcerovegetating donovanosis 171, 172
 - umbilicated craters 103–105
 - Union of Soviet Socialist Republics (USSR), probiotics 43
 - Ureaplasma* spp. 233–255
 - adhesion proteins 236
 - antigenic variation 236
 - arthritis 242
 - biology 234–235
 - clinical features 238–243
 - control 248–249
 - cytokine induction 237
 - diagnosis 243–247
 - enzymes 236–237
 - epidemiology 237–238
 - genomes 234–235, 236
 - IgA1 proteases 6
 - immunocompromised patients 242–243
 - infertility 240–242

- intracellular localization 237
- morphology 235–236
- pathogenesis 235–237
- pathogenicities 233–234
- prevention 248–249
- treatment 247–248
- urinary calculi 242
- urethritis
 - Chlamydia* 142, 148
 - gonorrhoea 188
 - mycoplasma 241
- urinary calculi 242
- urinary tract infections (UTIs)
 - Chlamydia* 139–141
 - circumcision effects 34
 - HIV transmission 70
 - probiotics 52
- urogenital tract
 - Chlamydia* 139–143, 148–150
 - gonorrhoea 188
 - mycoplasmas 238–242
- USSR *see* Union of Soviet Socialist Republics
- UTIs *see* urinary tract infections
- V**
- Vaa *see* variable-adherence-associated antigen
- vaccination
 - chancroid 285
 - Chlamydia* 151–152
 - genital herpes 93–94
 - gonorrhoea 201
 - human papilloma virus 130–131
 - syphilis 222–223
- vaginal microflora 46–49
- vaginitis
 - HIV 67
 - probiotics 50–51
- valacyclovir 90–92
- variable-adherence-associated antigen (Vaa) 236
- VDRL *see* Venereal Disease Research Laboratory
- vegetating donovanosis 171, 173
- Venereal Disease Research Laboratory (VDRL) tests 216
- Vergin, Ferdinand 43
- vesico-bullous tinea cruris 335
- videodermatoscopy 363–365
- Vif protein 63
- viral infections
 - circumcision effects 29–31, 35–36
 - contaminated blood/blood products 68
 - herpes 83–99
 - HIV 61–81
 - maternal–fetal transfer 68
 - M. contagiosum* 101–118
 - mucosal immunity 9–10
 - occupational risks 68–69
 - see also* herpes simplex viruses; human immunodeficiency virus; *Molluscum contagiosum*
- virulence factors
 - Candida* spp. 300–305
 - G. vaginalis* 260
 - H. ducreyi* 280–283
 - HIV 70–71
 - M. contagiosum* 102–103
 - mycoplasmas 235–237
 - N. gonorrhoeae* 183–185
 - T. pallidum* 214
 - T. vaginalis* 345–346
- vitamin deficiency, HIV 69
- voriconazole 315
- Vpr protein 63
- Vpu protein 63
- vulvovaginal candidosis (VVC) 293–327
 - acute/episodic infections 305–306
 - clinical features 305–306
 - diagnosis 306–311
 - differential diagnosis 311
 - epidemiology 294–300
 - host factors 301–305, 319
 - immunocompromised patients 315–316
 - non *albicans* 293–294, 299, 314–315
 - pathogenesis 300–305
 - pathogens 293–294
 - predisposition 301–305

vulvovaginal candidosis (VVC) (*cont'd*)
 pregnancy 300–301, 316
 probiotics 318
 recurrent 295–298, 306, 316–319
 risk factors 298
 treatment 311–319
 acute infection 312–316
 general principles 311–312
 recurrent 316–319

W

watchful waiting 108–109
WecA 282

wet mount microscopy 307–310,
 348–349
white paint dots 335
World Health Organization (WHO),
 probiotics 44–45

y

yaws (*Treponema pallidum* ssp.
 pertenue/TPE) see *Treponema*
 pallidum ssp. *pallidum*

Z

zymosan 304